KYTHERA Acquired by Allergan Inc 2015 Email Format

BiotechnologyUnited States51-200 Employees

Kythera is a United States-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing prescription treatments for aesthetic medicine. Its lead program, ATX-101, is being developed as an injectable therapy intended to reduce submental fat, a condition commonly referred to as a double chin. The company pursues research in hair and fat biology, as well as pigmentation modulation and facial contouring, to explore additional aesthetic applications. Its initial emphasis is on facial aesthetics, the largest segment of the aesthetic medicine market, with potential body indications considered for products with high aesthetic value.

Industry reporting notes that Allergan acquired Kythera Biopharmaceuticals, reflecting consolidation within the aesthetic medicine space. Beyond ATX-101, the company maintains an active research agenda aimed at identifying additional aesthetic indications and refining its understanding of facial contouring and related biology.

Sign up for free to view info

Company overview Employee directory